Romidepsin: A Guide to its Clinical Use in Cutaneous T-Cell Lymphoma
- 1 February 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in American Journal of Clinical Dermatology
- Vol. 13 (1), 67-71
- https://doi.org/10.2165/11208520-000000000-00000
Abstract
Intravenous romidepsin (Istodax®), a histone deacetylase inhibitor, is indicated in the US for the treatment of cutaneous T-cell lymphoma (CTCL) in adults who have received at least one prior systemic therapy. In two noncomparative trials in adults with relapsed, refractory, and/or advanced CTCL, romidepsin was associated with an overall response (i.e. complete or partial response) rate of 34% and 35%, and a complete response rate of 6% (in both trials). Romidepsin had an acceptable tolerability profile, with the most common grade 3 or 4 adverse events considered at least possibly related to romidepsin being hematologic or asthenic in nature.Keywords
This publication has 12 references indexed in Scilit:
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2010
- Chemical phylogenetics of histone deacetylasesNature Chemical Biology, 2010
- Current and Emerging Treatment Strategies for Cutaneous T-cell LymphomaDrugs, 2010
- Histone Deacetylase Inhibitors in Cancer TherapyJournal of Clinical Oncology, 2009
- Epigenetic Modifiers: Basic Understanding and Clinical DevelopmentClinical Cancer Research, 2009
- Histone deacetylase inhibitors in lymphoma and solid malignanciesExpert Review of Anticancer Therapy, 2008
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical ApplicationCurrent Drug Metabolism, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomasBritish Journal of Dermatology, 2003